An RCT of cannabinoid replacement therapy (Sativex®) for the management of treatment-resistant cannabis dependent patients

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1088902

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

This project is the first-ever outpatient RCT to test if the pharmaceutical cannabinoid Sativex can safely and cost-effectively deliver better treatment outcomes for patients seeking treatment for chronic cannabis dependence. Sativex is a mouth spray with equal parts THC and cannabidiol, and appears to have a safer pharmacological profile than illicit cannabis or synthetic THC alone. Thus Sativex may lead to lower rates of psychiatric adverse events and increased cannabis abstinence rates.

Funded Activity Details

Start Date: 01-01-2015

End Date: 01-01-2017

Funding Scheme: Project Grants

Funding Amount: $788,133.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Psychiatry (incl. Psychotherapy)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

addiction treatment | cannabis | randomised controlled trial (RCT) | relapse prevention | substance dependence

Related Links